The next generation of biotech blockbusters

The 2007 rate of new biologic approvals was slow, with only a handful of drugs squeaking through FDA review. But the pace is set to pick up in 2008. According to IMS Health, four biologics could receive FDA approval this year if they don't hit any stumbling blocks. Each of the drugs on this list has the potential for over a billion dollars in sales if all goes according to plan. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.